At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
XPH Spdr S&P Pharmaceuticals Etf
Post-Mkt 11-12 16:13:36 EST
67.02
-1.80
-2.62%
盘后67.02
+0.000.00%
16:10 EST
High68.67Low66.94Vol70.66K
Open68.67D1 Closing68.82Amplitude2.51%
Mkt Cap509.37MTradable Cap509.37MTotal Shares7.60M
T/O4.79MT/O Rate0.93%Tradable Shares7.60M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Why Is Penny Stock PepGen (PEPG) Up 114% Today?
TIPRANKS  ·  11-11 02:28
Why Is Penny Stock PepGen (PEPG) Up 114% Today?
WuXi Biologics (02269) Surges Over 4% on Largest Biosimilar Development Deal; UBS Sets Target Price at HK$62
Stock News  ·  11-04
WuXi Biologics (02269) Surges Over 4% on Largest Biosimilar Development Deal; UBS Sets Target Price at HK$62
Disc Medicine Stock (IRON) Soars Over 28% on a Phase 3 Trial Win
TIPRANKS  ·  10-19
Disc Medicine Stock (IRON) Soars Over 28% on a Phase 3 Trial Win
Citi: Sino Biopharmaceutical and STADA Form Biosimilar Strategic Partnership, "Buy" Rating Maintained
Stock News  ·  09-29
Citi: Sino Biopharmaceutical and STADA Form Biosimilar Strategic Partnership, "Buy" Rating Maintained
Sino Biopharmaceutical Jumps Nearly 4% as Subsidiary Strikes Strategic Biosimilar Deal with STADA, Securing Up to EUR53 Million in Upfront Payment
Stock News  ·  09-29
Sino Biopharmaceutical Jumps Nearly 4% as Subsidiary Strikes Strategic Biosimilar Deal with STADA, Securing Up to EUR53 Million in Upfront Payment
Patent Expirations and R&D Gaps Create a Looming Biologic Shortfall, Potentially Costing the U.S. Healthcare System $189 Billion
Stock News  ·  09-18
Patent Expirations and R&D Gaps Create a Looming Biologic Shortfall, Potentially Costing the U.S. Healthcare System $189 Billion
Fosun Pharma's Subsidiary Sees Regulatory Acceptance for Denosumab Biosimilar Candidate HLX14
Stock News  ·  09-11
Fosun Pharma's Subsidiary Sees Regulatory Acceptance for Denosumab Biosimilar Candidate HLX14
Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030
Deep News  ·  09-09
Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030
Structure weakness ‘disconnected’ from underlying data, says Jefferies
TIPRANKS  ·  09-09
Structure weakness ‘disconnected’ from underlying data, says Jefferies
Structure Therapeutics reports ACCG-2671, aleniglipron trial results
TIPRANKS  ·  09-08
Structure Therapeutics reports ACCG-2671, aleniglipron trial results
Henlius Shares Surge Nearly 8% on Strategic Alliance with Sandoz for Up to Ten Biosimilars
Deep News  ·  08-20
Henlius Shares Surge Nearly 8% on Strategic Alliance with Sandoz for Up to Ten Biosimilars
BMO starts Exelixis at Market Perform into patent cliff
TIPRANKS  ·  08-19
BMO starts Exelixis at Market Perform into patent cliff
AstraZeneca Explores Blockbuster Bristol-Myers Squibb Deal Reshaping Global Pharma Landscape
Stock News  ·  08-03
AstraZeneca Explores Blockbuster Bristol-Myers Squibb Deal Reshaping Global Pharma Landscape
HENLIUS Initiates First Patient Dosing in China for Phase 1 Study of Cetuximab Biosimilar HLX05-N in Metastatic Colorectal Cancer
Stock News  ·  07-08
HENLIUS Initiates First Patient Dosing in China for Phase 1 Study of Cetuximab Biosimilar HLX05-N in Metastatic Colorectal Cancer

Introduction

Company Name.
Spdr S&P Pharmaceuticals Etf
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
Issue price:
--